← back to the index
DV-006 cardiac electrophysiology 2011

The St. Jude Riata Leads — Wires That Wore Through Their Own Insulation

deathelectrical-failureinappropriate-shockinsulation-abrasioncardiac-electrophysiologycardiology2000s2010s
Patients implanted
~79,000 active U.S. leads at recall; >227,000 distributed worldwide
Failure or harm
Conductor externalization in ~19–27% (24% in 8 Fr); ≥2 extraction deaths, Hauser series tied ~22 deaths to shorting
In use
~9 yrs (sales 2001/2002 – Dec 2010; recalled 2011)
Status
Recalled (Class I)

Summary

When St. Jude Medical stopped selling its Riata and Riata ST defibrillator leads in December 2010 — eleven months before the FDA would classify the action as a Class I recall on 28 November 2011 — the gap between the device's premise and its behavior was already a matter of cardiac geometry: a lead engineered to carry high-voltage shocks reliably for the life of an implantable cardioverter-defibrillator (ICD) was instead destroying itself from the inside out. The silicone insulation that sheathed the inner cabling abraded against the conductors it was meant to protect, and the high-voltage wires worked their way through the insulation and externalized — poked out of the lead body — inside the patient's veins and heart. By the time sales stopped, more than 227,000 Riata-family leads had been distributed worldwide, roughly 79,000 of them still implanted in living U.S. patients, each one a wire that could fail to deliver a defibrillation shock at the one moment it was needed.

The danger of the Riata defect was not that it failed loudly but that it failed silently and electrically. A lead with externalized conductors could pass a routine pacing check on a clinic telemetry interrogation and still be incapable of completing a defibrillation circuit when a patient's heart fibrillated. The mechanism was an electrical short between the superior-vena-cava and right-ventricular shock coils — the kind of fault that does not announce itself until the device must actually defibrillate, and then does not. Imaging studies later found externalized conductors in roughly 19 to 27 percent of Riata leads examined, with the thicker 8 French models worse than the 7 French Riata ST, and meta-analysis tied externalization to a more than six-fold rise in electrical abnormality.

The Riata story is less a tale of a single catastrophic flaw than of how long a known reliability problem can travel before regulation catches it. The leads had been on the market since 2001–2002; St. Jude withdrew them commercially in December 2010 in favor of its newer Durata lead, which carried an Optim co-polymer coating the company argued would resist abrasion. Only in late 2011 — after a Minneapolis Heart Institute cardiologist, Dr. Robert Hauser, mined the FDA's MAUDE adverse-event database and published a series linking the Riata family to roughly 22 deaths from high-voltage shorting — did St. Jude issue the formal physician advisory the FDA then classified as Class I. St. Jude disputed Hauser's death count and demanded a retraction; the underlying signal stood. As with Medtronic's earlier Sprint Fidelis leads, the medical response was overwhelmingly to monitor in place rather than extract, because pulling a scarred-in lead from the heart carries its own mortal risk: at least two of the deaths in the recall record came not from the defect but from the extraction.

Timeline

2001
Riata launches
St. Jude Medical introduces the 8 French Riata silicone ICD lead, a high-voltage defibrillation lead with multiple inner conductors insulated by silicone.
2004
Riata ST follows
A thinner 7 French Riata ST version reaches market, narrowing the lead body while keeping the silicone insulation architecture.
2007–2008
The Fidelis precedent
Medtronic's Sprint Fidelis ICD leads are recalled for fracture; the episode sharpens scrutiny of small-diameter, high-voltage leads across the field.
2008–2010
Externalization signals accumulate
Case reports and imaging studies document Riata inner conductors abrading through the silicone and "externalizing" outside the lead body, with electrical shorts between shock coils.
Dec 2010
Quiet commercial withdrawal
St. Jude stops selling Riata and Riata ST leads, transitioning to the Durata lead with an Optim abrasion-resistant coating; existing implants stay in patients.
Aug–Nov 2011
Physician advisories escalate
St. Jude issues updated advisory letters to physicians quantifying externalized-conductor rates and recommending imaging surveillance.
28 Nov 2011
Voluntary recall initiated
St. Jude formally recalls Riata and Riata ST silicone leads; >227,000 had been distributed worldwide, ~79,000 still active in U.S. patients.
16 Dec 2011
FDA designates Class I
The FDA classifies the recall as Class I — its most serious category, reserved for defects that may cause serious injury or death.
Mar 2012
Hauser publishes the death series
Dr. Robert Hauser reports in Heart Rhythm that Riata high-voltage shorting is associated with roughly 22 deaths; St. Jude disputes the count and demands a retraction.
2012
The comparative recall analysis
A Heart Rhythm study compares Sprint Fidelis and Riata families, finding comparable post-recall failure-free survival and questioning the consistency and timing of post-market surveillance and reporting.
2012
Optim coating questioned
A subsequent paper documents abrasion in leads carrying the Optim coating — including the Durata successor — extending the reliability concern beyond Riata.
2015
Litigation settles
St. Jude Medical agrees to pay an estimated $14.25 million to resolve roughly 950 Riata-related claims; the leads remain monitored in tens of thousands of patients.

A Wire Built to Outlive Its Patient

An ICD lead is among the most demanding chronic implants in medicine: a thin insulated cable threaded through a vein into the right ventricle, expected to pace, sense, and on command deliver hundreds of volts to stop a lethal arrhythmia, for a decade or more, while flexing with every heartbeat. The Riata's promise, like every lead's, was reliability through that punishing duty cycle. Its architecture bundled multiple high-voltage conductors inside a silicone insulation body, and the later Riata ST narrowed the whole assembly to 7 French to ease implantation. The engineering tension was structural and unforgiving: thinner leads implant more easily and clot less, but leave less insulation between the energetic inner cables and the patient — and between the cables and each other. The Riata's silicone, flexing inside a beating heart against the very conductors it surrounded, abraded from the inside. The defect was not a manufacturing lapse on a single lot; it was an inherent wear behavior of the design, expressed across the population over years.

The Failure That Hid Behind a Normal Reading

What made Riata dangerous was the divergence between how it looked and how it worked. A clinician interrogating the device in a follow-up visit could read normal pacing thresholds and impedances and conclude the lead was sound, while an inner conductor had already externalized and a high-voltage short lurked between the shock coils. That short would not matter until the device had to defibrillate — and then it could shunt the therapeutic energy away from the heart, producing a failure to defibrillate, or trigger inappropriate shocks to a conscious patient. Detecting the worst faults required imaging the lead under fluoroscopy to see the externalized wire, or high-voltage testing that routine checks omit. Externalization appeared in roughly a fifth to a quarter of examined Riata leads, concentrated in the 8 French models, and carried a more than six-fold increase in electrical abnormality. Hauser's reading of the FDA's own MAUDE database surfaced the lethal tail: a cluster of deaths in which shorting prevented effective defibrillation. St. Jude contested the attribution and the number, but the existence of a silent, shock-defeating failure mode was no longer in dispute.

Recall as the Lagging Indicator

The chronology is the indictment. The leads sold from 2001; externalization was being reported by 2008–2010; St. Jude pulled them commercially in December 2010 in favor of Durata; and only in late 2011 — after an outside cardiologist had to data-mine the regulator's own adverse-event files to publish a death series — did the formal recall arrive, classified Class I on 16 December 2011. A 2012 comparative study found Riata and Sprint Fidelis had broadly similar post-recall failure-free survival despite being recalled at different points, and concluded the discrepancy raised questions about the consistency of post-market surveillance and manufacturer malfunction reporting. The clinical reckoning was constrained by the nature of the implant: extracting a lead scarred into the vasculature can kill, and at least two recall-associated deaths came from extraction itself, so guidance leaned toward imaging surveillance and lead monitoring rather than wholesale removal — the same conservative posture that had followed Fidelis. Litigation closed quietly: St. Jude settled roughly 950 claims for an estimated $14.25 million in 2015, a fraction of the device-fraud catastrophes that preceded it, because most patients were watched, not harmed.

Contributing Factors

01
An inside-out wear defect, not a defective lot
The Riata failed because its silicone insulation abraded against its own inner conductors across normal cardiac motion over years. This was an inherent design wear behavior expressed population-wide, not a manufacturing excursion fixable by a recall of bad lots — the hardest class of defect to bound, because every implanted unit is a candidate.
02
A failure mode invisible to routine surveillance
Externalized conductors and inter-coil shorts could coexist with normal pacing thresholds and impedances, so standard clinic interrogations missed them; only fluoroscopic imaging or high-voltage testing exposed the fault. A defect that passes the routine check is a defect that accumulates silently in the field.
03
The thin-lead trade-off
Narrowing the Riata ST to 7 French eased implantation but reduced insulation margin around energetic high-voltage cables. Optimizing for the implanting physician's convenience at the cost of long-term insulation robustness is a recurring lead-design failure pattern, seen again in Medtronic's Sprint Fidelis.
04
Withdrawal preceding recall by eleven months
St. Jude stopped selling Riata in December 2010 but the FDA Class I recall came in late 2011, after independent data-mining forced the issue. Treating quiet commercial substitution by a successor product as the response — rather than a prompt formal recall of the in-body hazard — let the surveillance and warning clock lag the known signal.
05
Regulation dependent on an outside whistleblower's database work
The lethal death cluster surfaced because one cardiologist, Robert Hauser, manually mined the FDA's MAUDE adverse-event files and published. When the detection of a Class I hazard depends on a volunteer investigator rather than the manufacturer's or regulator's own active surveillance, the system's post-market vigilance has failed structurally.

Aftermath

The Riata recall produced no bankruptcy and no statute; its durable consequence was epistemic. By exposing that two comparably failing lead families had been recalled on different timelines, and that a private cardiologist's database archaeology — not active manufacturer or FDA surveillance — had surfaced the death signal, the episode became a standing argument for stronger, prospective post-market monitoring of high-risk implants and for unique device identification that could actually track a lead through a patient's life. The clinical legacy was a generation of patients carrying monitored-but-not-removed leads, and a guideline literature on when imaging and extraction are justified against their own risks. The litigation closed for an estimated $14.25 million across roughly 950 claims in 2015 — small precisely because most harm was averted by watchful waiting rather than realized. The follow-on Durata lead with its Optim coating drew its own abrasion questions, keeping the underlying reliability problem alive after Abbott absorbed St. Jude in 2017. Today the Riata leads are the byword for the silent inside-out implant failure and for surveillance that lags the signal: the recall that arrived only after someone outside the company read the regulator's own files.

Lessons

  1. Treat any chronic high-energy implant as guilty of silent failure until imaging or load-realistic testing — not the routine interrogation — proves it sound; a defect that passes the standard check is the one that accumulates undetected in the field.
  2. When you optimize a device for ease of implantation by thinning its protective margin, document the long-term wear case explicitly, because the convenience is realized on day one and the failure on year five.
  3. Distinguish quietly substituting a successor product from recalling the deployed hazard: pulling a lead from sale does nothing for the tens of thousands already in patients, so start the formal warning and surveillance clock at withdrawal, not after.
  4. Build active post-market surveillance you do not have to be shamed into; if a Class I death signal can only be found by an outside clinician mining your regulator's adverse-event database by hand, your vigilance has already failed.
  5. For an in-body hazard, weigh remediation against its own mortality — extraction can kill — so let the response be governed by the realistic risk of both action and inaction, not by the reflex to remove.

References